Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. VAMINOLACT INTRAVENOUS SOLUTION [SIN07428P]

VAMINOLACT INTRAVENOUS SOLUTION [SIN07428P]

Active ingredients: VAMINOLACT INTRAVENOUS SOLUTION

Last updated 26 October 2025

Product Info

VAMINOLACT INTRAVENOUS SOLUTION

[SIN07428P]

Product information

Active Ingredient and Strength

ALANINE - 6.3 G/1,000 ML
ARGININE - 4.1 G/1,000 ML
ASPARTIC ACID - 4.1 G/1,000 ML
CYSTEINE - 1 G/1,000 ML
GLUTAMIC ACID - 7.1 G/1,000 ML
GLYCINE - 2.1 G/1,000 ML
HISTIDINE - 2.1 G/1,000 ML
ISOLEUCINE - 3.1 G/1,000 ML
LEUCINE - 7 G/1,000 ML
LYSINE - 5.6 G/1,000 ML
METHIONINE - 1.3 G/1,000 ML
PHENYLALANINE - 2.7 G/1,000 ML
PROLINE - 5.6 G/1,000 ML
SERINE - 3.8 G/1,000 ML
TAURINE - 300 MG/1,000 ML
THREONINE - 3.6 G/1,000 ML
TRYPTOPHAN - 1.4 G/1,000 ML
TYROSINE - 500 MG/1,000 ML
VALINE - 3.6 G/1,000 ML

Dosage Form

INJECTION

Manufacturer and Country

FRESENIUS KABI AUSTRIA GMBH - AUSTRIA

Registration Number

SIN07428P

Licence Holder

FRESENIUS KABI (SINGAPORE) PTE LTD

Forensic Classification

GENERAL SALE LIST

Anatomical Therapeutic Chemical (ATC) code

B05BA01

Indications
Vaminolact is indicated as a source of amino acids for protein synthesis and of taurine in infants and children requiring intravenous nutrition.

Dosage and administration
Recommended dosage

Vaminolact Dosage Table 1



* The dosage should be gradually increased to this value during the first week of life and the infusion should preferably be given continuously over 24 hours.

** The duration of infusion should be at least 8 hours.

Administration
Vaminolact may be infused into the same central of peripheral vein as glucose and fat emulsion by means of a Y-connector near the infusion site.
Discard any unused contents.

Contraindications
Vaminolact is contra-indicated in patients with inborn errors of amino acid metabolism, irreversible liver damage and in severe uremia when dialysis facilities are not available.